| Date |
Title |
| 19 Nov. 2024 |
Illumina announces expansion of TruSight Oncology portfolio |
| 12 Nov. 2024 |
Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says |
| 6 Nov. 2024 |
Illumina To Webcast Upcoming Investor Conferences |
| 4 Nov. 2024 |
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024 |
| 31 Oct. 2024 |
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting |
| 9 Oct. 2024 |
Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers |
| 7 Oct. 2024 |
Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024 |
| 3 Oct. 2024 |
Charles Dadswell to step down as General Counsel, Illumina initiates search for successor |
| 3 Sep. 2024 |
European Court of Justice rules in favor of Illumina in jurisdictional appeal |
| 27 Aug. 2024 |
FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies |
| 13 Aug. 2024 |
Illumina announces strategy to accelerate value creation |
| 6 Aug. 2024 |
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024 |
| 5 Aug. 2024 |
Illumina launches new oncology menu for NovaSeq X Series customers |
| 18 Jul. 2024 |
Illumina to Present Upcoming Strategy Update |
| 11 Jul. 2024 |
Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 |
| 9 Jul. 2024 |
Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base |
| 24 Jun. 2024 |
Illumina completes the divestiture of GRAIL |
| 11 Jun. 2024 |
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations |
| 4 Jun. 2024 |
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost |
| 3 Jun. 2024 |
Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares |
| 3 Jun. 2024 |
Illumina appoints Everett Cunningham Chief Commercial Officer |
| 29 May 2024 |
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO |
| 28 May 2024 |
Illumina releases 2023 Corporate Social Responsibility Report |
| 20 May 2024 |
Anna Richo joins Illumina's Board of Directors |
| 15 May 2024 |
Illumina To Webcast Upcoming Investor Conference |
| 6 May 2024 |
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL |
| 3 May 2024 |
Illumina To Webcast Upcoming Investor Conference |
| 2 May 2024 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024 |
| 12 Apr. 2024 |
Illumina's planned divestment of GRAIL approved by the European Commission |
| 9 Apr. 2024 |
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer |
| 4 Apr. 2024 |
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024 |
| 8 Feb. 2024 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023 |
| 9 Jan. 2024 |
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023 |
| 5 Jan. 2024 |
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test |
| 4 Jan. 2024 |
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024 |
| 4 Jan. 2024 |
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk |